This B5-2PP Flyer promotes Hyrimoz® (adalimumab), a biosimilar treatment for autoimmune conditions. It emphasizes its 6-week room-temperature stability, which is three times longer than Humira®, offering greater convenience for patients. The flyer also highlights the SensoReady® Pen, designed for easy and comfortable self-administration. The outdoor imagery reinforces the message of flexibility, mobility, and maintaining an active lifestyle while managing chronic conditions.